- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT07426757
Een open-label studie om PF-07994525 te evalueren bij deelnemers met gevorderde kankers
Een Open-label Fase 1-studie voor de Evaluatie van PF-07994525 bij Deelnemers met Geavanceerde Maligniteiten
This is an open-label, dose escalation and dose expansion study evaluating the safety, tolerability, Pharmacokinetic (PK), Pharmacodynamic (PD), and antitumor activity of PF-07994525 in participants with R/R MM.
The study will consist of 2 parts: Part 1 (Dose Escalation) will consist of PF-07994525 dose escalation to assess the safety, tolerability, and preliminary antitumor activity in participants with R/R MM. In Part 2 (Dose expansion), PF-07994525 may be evaluated in additional participants with R/R MM to further assess safety, PK, PD, and preliminary anti-tumor activity.
Studie Overzicht
Toestand
Interventie / Behandeling
Studietype
Inschrijving (Geschat)
Fase
- Fase 1
Contacten en locaties
Studiecontact
- Naam: Pfizer CT.gov Call Center
- Telefoonnummer: 1-800-718-1021
- E-mail: ClinicalTrials.gov_Inquiries@pfizer.com
Studie Locaties
-
-
Alberta
-
Calgary, Alberta, Canada, T2N 5G2
- Werving
- Arthur J.E. Child Comprehensive Cancer Centre
-
-
Ontario
-
Hamilton, Ontario, Canada, L8V 5C2
- Nog niet aan het werven
- Juravinski Cancer Centre
-
Toronto, Ontario, Canada, M5G2M9
- Werving
- University Health Network- Princess Margaret Cancer Centre
-
-
-
-
Colorado
-
Denver, Colorado, Verenigde Staten, 80218
- Werving
- Colorado Blood Cancer Institute
-
Denver, Colorado, Verenigde Staten, 80218
- Werving
- Presbyterian/St. Luke's Medical Center
-
-
Connecticut
-
New Haven, Connecticut, Verenigde Staten, 06511
- Werving
- Smilow Cancer Hospital Phase 1 Unit
-
New Haven, Connecticut, Verenigde Staten, 06510
- Werving
- Yale-New Haven Hospital-Yale Cancer Center
-
New Haven, Connecticut, Verenigde Staten, 06510
- Werving
- Smilow Cancer Hospital - Yale New Haven Health
-
New Haven, Connecticut, Verenigde Staten, 06511
- Werving
- Yale University - Smilow Cancer Hospital; C/O Thomas Ferencz, RPh, BCOP
-
North Haven, Connecticut, Verenigde Staten, 06473
- Werving
- Smilow Cancer Hospital - North Haven
-
-
Florida
-
Coral Gables, Florida, Verenigde Staten, 33146
- Werving
- Sylvester Comprehensive Cancer Center- The Lennar Foundation Medical Center
-
Coral Springs, Florida, Verenigde Staten, 33065
- Werving
- Sylvester Comprehensive Cancer Center - Coral Springs
-
Deerfield Beach, Florida, Verenigde Staten, 33442
- Werving
- University of Miami Hospital and Clinics - Deerfield Beach
-
Doral, Florida, Verenigde Staten, 33166
- Werving
- Sylvester Comprehensive Cancer Center- Doral
-
Hollywood, Florida, Verenigde Staten, 33021
- Werving
- Sylvester Comprehensive Cancer Center - Hollywood
-
Miami, Florida, Verenigde Staten, 33136
- Werving
- Sylvester Comprehensive Cancer Center
-
Miami, Florida, Verenigde Staten, 33136
- Werving
- University of Miami Hospital and Clinics
-
Miami, Florida, Verenigde Staten, 33176
- Werving
- Sylvester Comprehensive Cancer Center- Kendall
-
North Miami, Florida, Verenigde Staten, 33181
- Werving
- Sylvester Comprehensive Cancer Center - Sole Mia
-
Plantation, Florida, Verenigde Staten, 33324
- Werving
- Sylvester Comprehensive Cancer Center - Plantation
-
-
Georgia
-
Atlanta, Georgia, Verenigde Staten, 30308
- Werving
- Emory University Hospital Midtown
-
Atlanta, Georgia, Verenigde Staten, 30322
- Werving
- Emory University Hospital
-
Atlanta, Georgia, Verenigde Staten, 30322
- Werving
- Winship Cancer Institute, Emory University
-
-
Ohio
-
Columbus, Ohio, Verenigde Staten, 43210
- Werving
- The James Cancer Hospital and Solove Research Institute
-
Columbus, Ohio, Verenigde Staten, 43210
- Werving
- Ohio State University Hospitals
-
Columbus, Ohio, Verenigde Staten, 43210
- Werving
- The James Outpatient Care West Campus
-
-
Tennessee
-
Nashville, Tennessee, Verenigde Staten, 37203
- Werving
- Sarah Cannon Research Institute - Pharmacy
-
Nashville, Tennessee, Verenigde Staten, 37203
- Werving
- Tristar BMT
-
Nashville, Tennessee, Verenigde Staten, 37203
- Werving
- SCRI Oncology Partners
-
Nashville, Tennessee, Verenigde Staten, 37203
- Werving
- TriStar Centennial Medical center
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Participants aged 18 years or older (or the minimum age of consent in accordance with local regulations) at the time of informed consent.
- Prior diagnosis of MM as defined according to IMWG criteria (Rajkumar et al. 2014)
Measurable disease based on IMWG criteria as defined by at least 1 of the following:
-
Serum M-protein >0.5 g/dL by serum protein electrophoresis (SPEP)
-
Urinary M-protein excretion >200 mg/24 hours by urine protein electrophoresis (UPEP)
-
Serum immunoglobulin Free Light Chain (FLC) ≥10 mg/dL (≥100 mg/L) AND abnormal serum immunoglobulin kappa to lambda FLC ratio (<0.26 or >1.65)
- Participants must be refractory to, or intolerant to, all established therapies known to provide clinical benefit in multiple myeloma that are an appropriate therapeutic option, in the judgement of the investigator. A minimum of 3 prior lines of therapy are required.
- Eastern Cooperative Oncology Group (ECOG) performance status 0-1.
Exclusion Criteria:
- Active plasma cell leukemia, Smoldering MM, Waldenströms macroglobulinemia, Amyloidosis, POEMS Syndrome.
- Autologous stem cell transplant within 12 weeks prior to enrollment or active Graft-versus-host disease (GVHD).
- Active or suspected cerebral/meningeal disease related to the underlying malignancy.
- Any active, uncontrolled bacterial, fungal, or viral infection, including (but not limited to) COVID-19, Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), known HIV or AIDS related illness, unless deemed not clinically significant by the investigator (eg, onychomycosis).
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: NVT
- Interventioneel model: Sequentiële toewijzing
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Part 1
Monotherapy Dose Expansion |
Oral administration Oral administration |
|
Experimenteel: Part 2
Monotherapy Dose Escalation |
Oral administration |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Type, incidence and severity of participants with adverse events (AEs)
Tijdsspanne: From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
Type, incidence, severity (graded by National Cancer Institute Common Terminology Criteria for Adverse Events [NCI CTCAE] version 5.0), timing, seriousness, and relatedness of adverse events (AEs) |
From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
|
Type, incidence and severity of participants with laboratory abnormalities
Tijdsspanne: From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
Type, incidence, and severity (graded by NCI CTCAE version 5.0) of laboratory abnormalities |
From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
|
Number of participants with dose modifications
Tijdsspanne: From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
Frequency of dose modifications (eg, dose delay, treatment interruptions, dose reductions, and treatment discontinuations) due to AEs |
From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
|
Part 1: Number of Participants With Dose-limiting Toxicities (DLTs)
Tijdsspanne: Baseline to end of DLT evaluation period
|
Occurrence of DLTs as defined by the protocol |
Baseline to end of DLT evaluation period
|
|
Part 1: Recommended Monotherapy Dose for Expansion (RDE)
Tijdsspanne: From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
RDE will be based on cumulative safety, preliminary antitumor activity and pharmacokinetics findings |
From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
|
Part 2: Recommended Dose for future development
Tijdsspanne: From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
Safety, and preliminary anti-tumor activity |
From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Objectieve responsratio (ORR) volgens de International Myeloma Working Group (IMWG) responscriteria zoals bepaald door de onderzoeker.
Tijdsspanne: Vanaf baseline tot de datum van de eerste documentatie van ziekteprogressie, overlijden of start van nieuwe antikankertherapie (ongeveer 2 jaar)
|
Vanaf baseline tot de datum van de eerste documentatie van ziekteprogressie, overlijden of start van nieuwe antikankertherapie (ongeveer 2 jaar)
|
|
|
Complete response rate (CRR) volgens de International Myeloma Working Group (IMWG) responscriteria zoals bepaald door de onderzoeker.
Tijdsspanne: Baseline tot de datum van de eerste documentatie van ziekteprogressie, overlijden, of start van nieuwe antikankertherapie (ongeveer 2 jaar)
|
Baseline tot de datum van de eerste documentatie van ziekteprogressie, overlijden, of start van nieuwe antikankertherapie (ongeveer 2 jaar)
|
|
|
Tijd tot respons (TTR) volgens IMWG zoals bepaald door de onderzoeker
Tijdsspanne: Vanaf de startdatum tot de datum van de eerste documentatie van ziekteprogressie, overlijden, of start van nieuwe antitumortherapie (ongeveer 2 jaar)
|
Vanaf de startdatum tot de datum van de eerste documentatie van ziekteprogressie, overlijden, of start van nieuwe antitumortherapie (ongeveer 2 jaar)
|
|
|
Duur van respons (DOR) volgens IMWG zoals bepaald door de onderzoeker
Tijdsspanne: Baseline tot de datum van de eerste documentatie van ziekteprogressie, overlijden, of start van nieuwe antikankertherapie (ongeveer 2 jaar)
|
Baseline tot de datum van de eerste documentatie van ziekteprogressie, overlijden, of start van nieuwe antikankertherapie (ongeveer 2 jaar)
|
|
|
Duur van complete respons (DOCR) volgens IMWG zoals vastgesteld door onderzoeker
Tijdsspanne: Baseline tot de datum van de eerste documentatie van ziekteprogressie, overlijden, of start van nieuwe antikankertherapie (ongeveer 2 jaar)
|
Baseline tot de datum van de eerste documentatie van ziekteprogressie, overlijden, of start van nieuwe antikankertherapie (ongeveer 2 jaar)
|
|
|
Progressievrije overleving (PFS) volgens IMWG zoals bepaald door de onderzoeker
Tijdsspanne: Baseline tot de datum van de eerste documentatie van ziekteprogressie, overlijden of start van nieuwe antikankertherapie (ongeveer 2 jaar)
|
Baseline tot de datum van de eerste documentatie van ziekteprogressie, overlijden of start van nieuwe antikankertherapie (ongeveer 2 jaar)
|
|
|
Overall survival (OS)
Tijdsspanne: Baseline tot de datum van de eerste documentatie van ziekteprogressie, overlijden of start van nieuwe antikankertherapie (ongeveer 2 jaar)
|
Baseline tot de datum van de eerste documentatie van ziekteprogressie, overlijden of start van nieuwe antikankertherapie (ongeveer 2 jaar)
|
|
|
Single, Multiple Dose and food effect: Maximum Observed Concentration (Cmax)
Tijdsspanne: From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
Pharmacokinetic (PK) assessments for PF-07994525 |
From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
|
Single, Multiple Dose and food effect: Time to Maximum concentration (Tmax)
Tijdsspanne: From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
Pharmacokinetic (PK) assessments for PF-07994525 |
From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
|
Single, Multiple Dose and food effect: AUC from time zero to time of last measurable concentration (AUClast)
Tijdsspanne: From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
Pharmacokinetic (PK) assessments for PF-07994525 |
From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
|
Single Dose and food effect: Terminal Elimination half-life (t1/2) as data permit
Tijdsspanne: From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
Pharmacokinetic (PK) assessments for PF-07994525 |
From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
|
Single Dose and food effect: AUC versus time curve from time 0 extrapolated to infinity (AUCinf) as data permit
Tijdsspanne: From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
Pharmacokinetic (PK) assessments for PF-07994525 |
From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
|
Single, Multiple Dose and food effect: apparent clearance of drug (CL/F) as data permit
Tijdsspanne: From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
Pharmacokinetic (PK) assessments for PF-07994525 |
From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
|
Single, Multiple Dose and food effect: Apparent volume of distribution during terminal phase (Vz/F) as data permit
Tijdsspanne: From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
Pharmacokinetic (PK) assessments for PF-07994525 |
From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
|
Multiple Dose: AUC at steady state over the dosing interval (AUCtau) as data permit
Tijdsspanne: From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
Pharmacokinetic (PK) assessments for PF-07994525 |
From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
|
Multiple Dose: Cmin as data permit
Tijdsspanne: From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
Pharmacokinetic (PK) assessments for PF-07994525 |
From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
|
Multiple Dose: Accumulation ratio (Rac) as data permit
Tijdsspanne: From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
Pharmacokinetic (PK) assessments for PF-07994525 |
From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
|
AUC from time zero to time of last measurable concentration (AUClast)
Tijdsspanne: From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
PK parameters of CYP3A4 probe substrate midazolam with and without PF-07994525 |
From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
|
Time to Maximum concentration (Tmax)
Tijdsspanne: From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
PK parameters of CYP3A4 probe substrate midazolam with and without PF-07994525 |
From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
|
Maximum Observed Concentration (Cmax)
Tijdsspanne: From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
PK parameters of CYP3A4 probe substrate midazolam with and without PF-07994525 |
From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
Medewerkers en onderzoekers
Sponsor
Onderzoekers
- Studie directeur: Pfizer CT.gov Call Center, Pfizer
Publicaties en nuttige links
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- C6331001
- KAT2i (Andere identificatie: Alias Study Number)
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Beschrijving IPD-plan
Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .